OBIO News Guest User OBIO News Guest User

PreCAAP Company: iamsick.ca featured in StartUp Here TORONTO

Stay Away from Me...I Am Sick

OBIO Pre-CAAP Company iamsick.ca knows that the last thing you want to do when you are sick is look for a family doctor, a walk-in-clinic or a nearby pharmacy.  The new app informs patients on what clinics are nearby (in your actual area) and pharmacies and to find out what clinics are accepting new patients (great when you move to a new area!) and book appointments online.

For the full article click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: Eve Medical's Eve Kit Highlighted on CBC News

Former OBIO CAAP company Eve Medical was highlighted on CBC News. The EVE Kit is gearing up to be ready for purchase online this fall!

"Canadian women may be able to self-administer tests for sexually transmitted infections from the comfort of their own homes, for less than $100." 

CEO Jessica Ching says, the hope is to make "it more convenient for women to test for HPV which could guard against cervical cancer."

Follow their progress and updates on Twitter @evemedical

For the CBC feature click here

Read More
OBIO News Guest User OBIO News Guest User

Pre-CAAP: Winterlight Labs, SensOR Medical Laboratory, TopSpin360, iMerciv - Winners of 2016 ONtrepreneurs Program

Aug 8, 2016 - 4 OBIO Pre-CAAP companies have been selected as winners of the Ontario Brain Institute (OBI) 2016 ONtrepreneurs Program!

Congratulations to  Winterlight Labs, SensOR Medical Laboratory, TopSpin360 & iMerciv!

The ONtrepreneurs (Ontario Neurotech Entrepreneurs) Program helps "Ontario neurotech entrepreneurs take their ideas from the lab to the marketplace."

This year's winners participated in a pitching competition to a panel of "expert judges from organizations including Yocto Law, Biomedical Zone, Emmetros, AGE-WELL, Ironstone Product Development Inc. and OBI."

$300,000 ($50,000 each) has been awarded to the winners to assist with commercializing their neurotechnologies.

For the full press release, click here

 

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: CellAegis' autoRIC® Device Clinically Implemented in Peel-Halton Region

CellAegis autoRIC® Device, which reduces heart damage in ischemic heart disease, is now being clinically implemented in Peel-Halton Region, West of Toronto. The autoRIC® Device is being used to treat all patients having heart attacks, in addition to standard treatment. The FIRST study (Field Implementation of autoRIC Device in STEMI (ST-segment Myocardial Infarction)) is the first clinical implementation of our device across an entire region, and is expected to be the first of many such clinical implementations, as the benefit of Remote Ischemic Conditioning therapy becomes more widely utilized.

For the full press release click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: KA Imaging Receives $1M to develop low-cost lung screening

July 21, 2016 KITCHENER — A startup developing a low-cost, high-resolution digital X-ray imager to detect lung disease in developing nations has received a $1-million boost.

The new money from federally funded Grand Challenges Canada will help KA Imaging build a prototype and test it in the field in Zambia by the end of the year.

For the full article click here

For the Grand Challenges press release, click here

Read More
OBIO News Guest User OBIO News Guest User

OBIO Innovation Agenda Leader

OBIO Innovation Agenda Leader

On July 21st, Gail Garland, CEO of OBIO attended the  Federal Government's Global Science Excellence Roundtable, part of the Inclusive Innovation Agenda Strategy held in Ottawa.

The ideas generated during the session will be consolidated and presented to Minister Navdeep Bains for consideration as part of the Inclusive Innovation Agenda report.

For the full report, click here

For the Innovation Submission page, click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: iTP Biomedica Launches BladderPredict, A State-Of-The-Art Diagnostic To Manage Early Stage Bladder Cancer

July 19, 2016 TORONTO – iTP Biomedica Corp., a developer of proprietary whole transcriptome-based cancer diagnostics, today announced the launch of BladderPredict, a groundbreaking next-generation sequencing-based test that will for the first time assist uro-pathologists in assigning disease grade in early stage bladder cancer, and urologists and uro-oncologists in managing the disease.

For the full press release, click here

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Synaptive Medical Receives Health Canada Approval For Brightmatter Guide: A Surgical Navigation Solution

July 5, 2016 TORONTO – Synaptive Medical Inc., a company focused on global commercialization of innovative solutions, announced the approval from Health Canada to market BrightMatterTM Guide. This new technology is part of a solution for health care providers that includes informatics, imaging, surgical planning, navigation and advanced optics.

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Ontario's Health Technologies Fund now accepting applications

July 4, 2016, TORONTO - Ontario's $20 million Health Technologies Fund (HTF) is open for business.

Announced in May by William Charnetski, Ontario's Chief Health Innovation Strategist, the Fund will support the development of leading, market-ready, made-in-Ontario health technologies by accelerating prototyping, evaluation, adoption and diffusion in the Ontario health care sector.

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Sernova Increases Private Placement to $4,200,000

June 29, 2016, London ON – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the “Units”) at $0.25 per Unit, to accommodate additional over-subscriptions (see news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Sernova Announces $2,000,000 First Closing of Private Placement - Due to Oversubscription, Offering Increased to $3,750,000

June 27, 2016 LONDON, ONTARIO Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the “Units”) at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016.

Read More
OBIO News Guest User OBIO News Guest User

RESI Toronto Receives Two Thumbs Up

June 24, 2016 This year Toronto hosted the inaugural RESI conference on June 23, bringing together hundreds of companies and investors from across the globe in areas of biotech, digital health, medical devices and consumer health. 

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Sernova Announces Non-brokered Private Placement - Net proceeds to fund collaborations and a US-based clinical trial

June 21, 2016 LONDON, ONTARIO – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the “Units”) at a price of $0.25 per Unit.

Read More